CClinicalTrials.gg
CompletedNCT03267563ROSEUpdated Apr 15, 2026Results posted

Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women

An interventional study of EIAU and LICF in Depression, Postpartum, sponsored by Michigan State University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Michigan State University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postpartum depression (PPD) is common and can have lasting consequences for mother and child. ROSE is an intervention to prevent PPD, delivered during pregnancy in outpatient prenatal settings. ROSE has been found to significantly reduce cases of PPD in multiple randomized trials in community prenatal settings with racially and ethnically diverse low-income pregnant women. Requests for ROSE training and recent policy changes supporting payment for comprehensive perinatal services to underserved populations suggest a context ripe for embedding ROSE in prenatal clinics long-term. Given the need for return on investment studies about sustainment efforts, we propose a Sequential Multiple Assignment Randomized (SMART) Trial of the effectiveness and cost-effectiveness of a stepwise approach to sustainment of ROSE in 90 outpatient clinics providing prenatal care to pregnant women on public assistance in 6 U.S. states. In Year 1, all clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). At the first time at which a clinic is determined to be at risk for failure to sustain (i.e., at 3, 6, 9, 12, 15 months), that clinic will be randomized to receive either: (1) no additional implementation support (i.e., EIAU only), or (2) low-intensity coaching and feedback (LICF). If clinics receiving LICF are still found to be at risk at subsequent assessments, they will be randomized to either (1) EIAU + LICF only, or (2) high-intensity coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. Outcomes include: 1. Sustainment of core program elements at each time point and total length of time ROSE services were provided and were provided with at least moderate fidelity. 2. Health impact (PPD rates over time at each clinic) and reach. 3. ROI (costs, cost-offsets, and cost-effectiveness) of each sustainment step. Hypothesized mechanisms include sustainment of clinical and organizational capacity to deliver core elements, and engagement/ownership. The study will also examine predictors, tailoring variables, and implementation processes to determine which kinds of clinics need which level of sustainment support and when. To our knowledge, this study will be the first randomized trial evaluating the ROI of a stepped approach to sustainment, a critical unanswered question in implementation science.

Read the detailed description

A recent expert consensus report concluded that, "Little is known about how well or under what conditions health innovations are sustained and their gains maintained once they are put into practice. Implementation science typically focuses on uptake by early adopters. The later-stage challenges of sustaining evidence-supported interventions receive too little attention." This report placed high priority on conducting return on investment (ROI) studies to determine how much is gained when effective programs are sustained, and cost-benefit trade-offs for effort required to sustain.1 Information is especially needed for preventive behavioral health interventions for adults in outpatient medical (e.g., primary care; OBGYN) settings.

Postpartum depression (PPD) is common and can have serious and lasting consequences for mother and child, including maternal increased risk for suicide, compromised functional status, and adverse infant developmental outcomes. Prevalence of PPD is \~13% in the 12 weeks after childbirth, with rates up to 50% among low-income women, who are especially vulnerable to the consequences of PPD. Outpatient clinics offering prenatal care are an opportune place to deliver PPD prevention services because most women will visit while pregnant. Recent guidelines suggest that prenatal clinics should screen for PPD after birth and refer once it is identified. Unfortunately, prenatal clinics do not routinely do anything to prevent PPD from occurring.

The ROSE Program (Reach Out, Stay Strong, Essentials for mothers of newborns) is a small-group intervention to prevent PPD that is delivered during pregnancy in outpatient prenatal settings. ROSE is the only PPD preventative intervention that (1) has been found to significantly reduce cases of PPD in multiple randomized trials, and (2) has been tested in community prenatal settings with racially and ethnically diverse low income pregnant women. ROSE consists of four 90-minute group sessions and a 50-minute individual booster session after delivery. Requests for ROSE training in Philadelphia and nationwide in Japan, and recent policy changes supporting payment for comprehensive perinatal services (including behavioral health care) to underserved populations all suggest a context ripe for embedding ROSE in prenatal clinics long-term. Given the need for ROI studies about sustainment efforts and that ROSE is well-positioned for implementation and sustainment research, we propose a Sequential Multiple Assignment Randomized (SMART) Trial of the effectiveness and cost-effectiveness of a stepwise approach to sustainment of ROSE in 90 outpatient clinics providing prenatal care to pregnant women on public assistance accross the US. Our conceptual framework comes from RE-AIM and a review on sustainment by Co-I Wiltsey-Stirman,3 with sustainment strategies based on the Replicating Effective Programs (REP) framework. All clinics will receive enhanced implementation as usual (EIAU; initial training + tools for sustainment). Clinics will be assessed using surveys and qualitative interviews 9 times over 2.5 years after receiving EIAU. Clinics at risk for failure to sustain operationally (defined as no ROSE intervention in 3 months and none planned) and/or clinically (defined as low fidelity to ROSE core elements) will be randomized to receive additional sustainment support for up to 18 months after baseline. At the first time period at which a clinic is determined to be at risk (i.e., at 3, 6, 9, 12, or 15 months), that clinic will be randomized to receive either: (1) no additional implementation support (EIAU only), or (2) EIAU plus low-intensity (every 3 months) coaching and feedback (LICF). If clinics receiving LICF are still at risk at subsequent monitoring periods, they will be randomized to (1) EIAU + LICF only, or (2) EIAU + LICF + high-intensity (monthly) coaching and feedback (HICF). Additional study follow-up interviews will occur at 18, 24, and 30 months, but no implementation intervention will occur after 18 months. We will assess costs and benefits of sustainment strategies. Aims are to:

Compare effectiveness of each sustainment step for the following final and proximal OUTCOMES:

  1. Sustainment of core program elements at each time point, and total length of time in weeks that: (i) any ROSE services were provided, and (ii) were provided with adequate fidelity to core elements (primary).
  2. Health impact (e.g., PPD rates over time at each clinic) and reach (number of patients enrolled in and completing the ROSE program).
  3. Return on Investment (costs and cost-effectiveness of each sustainment step).
  4. Hypothesized mechanisms include sustainment of: (a) clinical and organizational capacity to deliver core elements, and (b) a sense of engagement/ownership by key clinic staff, Examine predictors and processes to determine which kinds of clinics need which level of support.
  5. Explore which clinic characteristics (e.g., organizational and state policy contexts) and hypothesized mechanisms (Aim 4) are associated with best sustainment to determine tailoring variables for choosing/sequencing EIAU, LICF, HICF in the future.
  6. Document implementation/sustainment effort processes, their timing relative to desired outcomes, critical incidents to explore factors most related to sustainment after accounting for hypothesized mechanisms.

To our knowledge, this study will be the first randomized trial evaluating the ROI of a stepped approach to sustainment, a critical unanswered question in implementation science. The study will also examine a set of strategies to promote sustainment of an effective PPD prevention intervention for low-income women, reducing negative consequences for mother and child. The proposal directly addresses the goal of PAR-16-238 to conduct longitudinal studies on "factors that contribute to the sustainability of evidence-based interventions," to test strategies to improve quality of care among underserved populations, examine mediators and moderators, and examine cost-effectiveness or other economic outcomes. Thus, the study will advance implementation science, knowledge of implementation science mechanisms, and clinical care for an at-risk population.

02

Conditions studied

  • Depression, Postpartum

Keywords

  • prevention
  • implementation
  • sustainment
  • perinatal
  • pregnancy
  • postpartum
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Study enrollment began with enrollment of clinics. Inclusion criteria for clinics were:

  1. outpatient,
  2. provide prenatal services,
  3. estimate at least 30% of their pregnant patients received some kind of public assistance (such as federal or state cash assistance, food stamps, subsidized housing, and/or health insurance such as Medicaid),
  4. have at least 3 new pregnant people per month on average (i.e., enough patient flow to run ROSE), and
  5. agree to study procedures. Inclusion criteria were for the clinic itself; once the clinic was included, any pregnant person within the agency could receive ROSE.

Participants were clinic personnel, and they were enrolled within clinic. Their inclusion criteria were:

  1. age 18 or older
  2. someone chosen by the agency to respond to quarterly survey questions about clinical delivery of ROSE (the "clinical respondent");
  3. someone chosen by the agency to respond to quarterly surveys about operational (billing, scheduling) aspects of ROSE delivery (the "operational respondent," which could be the same or a different person than the "clinical respondent");
  4. all ROSE facilitators for the agency (who completed self-rated ROSE adherence forms).

Exclusion Criteria:

  • None
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Enhanced implementation as usual (EIAU)

    EIAU: Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment.

    Behavioral: EIAU · Behavioral: LICF · Behavioral: HICF

  • Experimental
    Low-intensity coaching and feedback (LICF)

    Low-intensity (every 3 months) coaching and feedback (LICF): Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone "booster" meeting.

    Behavioral: LICF · Behavioral: HICF

  • Experimental
    High-intensity coaching and feedback (HICF)

    High-intensity (every month) coaching and feedback (HICF): Enhanced implementation plus high intensity will have received initial training and problem-solving plus planning for sustainment and after that every month will receive one clinical and one operational telephone "booster" meeting.

    Behavioral: HICF

Interventions

  • BehavioralEIAU

    Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,

  • BehavioralLICF

    Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone "booster" meeting.

  • BehavioralHICF

    Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.

05

What researchers measure

Primary outcomes

  1. Proportion Sustainment of Core Program Elements

    Proportion sustainment of ROSE's core program elements, assessed using the ROSE Session-by-Session Adherence Scale, was defined as the mean proportion of core elements delivered that should have been delivered at each ROSE session over the time period (zero if no sessions were completed). Potential range is 0 to 1, higher score reflects better outcome.

    Time frame: Average over months 3, 6, 9, 12, 15, 18, 24, and 30 after baseline

  2. Number of Months of Sustained ROSE Delivery

    Number of months when ROSE was delivered was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.

    Time frame: Summary of total number of months over 30 month study period.

  3. Number of Months of Sustained ROSE Delivery With Fidelity

    Number of months when ROSE was delivered with fidelity was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.

    Time frame: Summary of total number of months over 30 month study period.

Secondary outcomes

  1. Annualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months

    Surveys at each time point included questions for the clinic to report the number of people who attended at least one ROSE session and the number served by the clinic in the past 12 months. Total numbers attending ROSE over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.

    Time frame: Summary over 30 month study period.

  2. Annualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months

    Surveys at each time point included questions for the clinic to report the number of people who attended at least three ROSE sessions and the number served by the clinic in the past 12 months. Total numbers attending at least three ROSE sessions over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received at least three sessions of ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.

    Time frame: Summary over 30 month study period.

06

Results

Posted Apr 15, 2026
Limitations and caveats
The study period included COVID-19 pandemic with a temporary pause in randomizations.

Participant flow

Participant flow — Overall Study
MilestoneEIAU Only RespondersEIAU Only Followed by Continued EIAU Only for Non-responders to Initial EIAUEIAU Only Followed by LICF for Non-responders to Initial EIAU, Responders to LICFEIAU Followed by LICF for Non-responders to EIAU, Non- Responders to LICF Continued With LICFEIAU Followed by LICF for Non-responders to EIAU, Non- Responders to LICF Also Received HICFDrop-outs After EIAU+LICF Prior to Determining Response to EIAU+LICFEIAU Drop-out Prior to Determining Response to EIAU
Started701821242412
Completed701821242412
Not completed0000000

Outcome measures

PrimaryProportion Sustainment of Core Program Elements

Proportion sustainment of ROSE's core program elements, assessed using the ROSE Session-by-Session Adherence Scale, was defined as the mean proportion of core elements delivered that should have been delivered at each ROSE session over the time period (zero if no sessions were completed). Potential range is 0 to 1, higher score reflects better outcome.

Time frame:
Average over months 3, 6, 9, 12, 15, 18, 24, and 30 after baseline
Reported as:
Least squares mean · proportion of sessions
Proportion Sustainment of Core Program Elements
proportion of sessionsFirst Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF AddedFirst Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAUSecond Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF AddedSecond Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF
Proportion Sustainment of Core Program Elements0.34 ± 0.050.18 ± 0.090.43 ± 0.080.13 ± 0.09
Statistical analysis
  • First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added vs First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU · Mixed Models Analysis · p = .12 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Mean difference (final values): 0.16 · 95% CI -0.04 to 0.37Difference mean of EIAU+LICF minus mean of EIAU.
  • Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added vs Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF · Mixed Models Analysis · p = .02 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Mean difference (final values): 0.30 · 95% CI 0.05 to 0.55Difference mean of EIAU+LICF+HICF minus mean of EIAU+LICF.
PrimaryNumber of Months of Sustained ROSE Delivery

Number of months when ROSE was delivered was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.

Time frame:
Summary of total number of months over 30 month study period.
Reported as:
Least squares mean · months
Number of Months of Sustained ROSE Delivery
monthsFirst Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF AddedFirst Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAUSecond Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF AddedSecond Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF
Number of Months of Sustained ROSE Delivery7.00 ± 1.095.07 ± 1.957.11 ± 1.813.38 ± 1.87
Statistical analysis
  • First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added vs First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU · Regression, Linear · p = .39 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Mean difference (final values): 1.93 · 95% CI -2.49 to 6.34Difference mean of EIAU+LICF minus mean of EIAU.
  • Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added vs Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF · Regression, Linear · p = .17 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Mean difference (final values): 3.73 · 95% CI -1.65 to 9.10Difference mean of EIAU+LICF+HICF minus mean of EIAU+LICF.
PrimaryNumber of Months of Sustained ROSE Delivery With Fidelity

Number of months when ROSE was delivered with fidelity was tracked using calendar method. Potential range is 0 to 30 months, higher score reflects better outcome.

Time frame:
Summary of total number of months over 30 month study period.
Reported as:
Least squares mean · months
Number of Months of Sustained ROSE Delivery With Fidelity
monthsFirst Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF AddedFirst Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAUSecond Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF AddedSecond Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF
Number of Months of Sustained ROSE Delivery With Fidelity6.02 ± 0.914.41 ± 1.796.68 ± 1.452.20 ± 1.54
Statistical analysis
  • First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added vs First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU · Regression, Linear · p = .42 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Mean difference (final values): 1.61 · 95% CI -2.34 to 5.57Difference mean of EIAU+LICF minus mean of EIAU.
  • Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added vs Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF · Regression, Linear · p = .04 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Mean difference (final values): 4.48 · 95% CI 0.16 to 8.79Difference mean of EIAU+LICF+HICF minus mean of EIAU+LICF.
SecondaryAnnualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months

Surveys at each time point included questions for the clinic to report the number of people who attended at least one ROSE session and the number served by the clinic in the past 12 months. Total numbers attending ROSE over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.

Time frame:
Summary over 30 month study period.
Reported as:
Median · percentage of pregnant people
Annualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months
percentage of pregnant peopleFirst Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF AddedFirst Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAUSecond Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF AddedSecond Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF
Annualized Percent of Pregnant People Attending at Least One ROSE Session Over 30 Months1.07 (0 to 4.80)0.46 (0.07 to 11.00)1.62 (0.10 to 7.67)0 (0 to 2.07)
Statistical analysis
  • First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added vs First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU · Wilcoxon (Mann-Whitney) · p = .51 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Median difference (final values): 0.61Difference of distributions of EIAU+LICF versus EIAU. Difference of medians is reported, but the test is non-parametric (comparison of the two distributions and not just medians).
  • Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added vs Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF · Wilcoxon (Mann-Whitney) · p = .08 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Median difference (final values): 1.62Difference of distributions of EIAU+LICF+HICF versus EIAU+LICF. Difference of medians is reported, but the test is non-parametric (comparison of the two distributions and not just medians).
SecondaryAnnualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months

Surveys at each time point included questions for the clinic to report the number of people who attended at least three ROSE sessions and the number served by the clinic in the past 12 months. Total numbers attending at least three ROSE sessions over 30 months were annualized (divided by 2.5), then divided by number of pregnant people served in the 12 months prior to baseline and multiplied by 100% to estimate percent of pregnant patients at each agency who received at least three sessions of ROSE over 30 months. Potential range is 0 to 100 percent. Higher score reflects better outcome.

Time frame:
Summary over 30 month study period.
Reported as:
Median · percentage of pregnant people
Annualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months
percentage of pregnant peopleFirst Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF AddedFirst Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAUSecond Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF AddedSecond Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF
Annualized Percent of Pregnant People Attending at Least Three ROSE Sessions (of Five) Over 30 Months0.10 (0 to 2.88)0.06 (0 to 10)0.38 (0 to 4.27)0 (0 to 0.01)
Statistical analysis
  • First Randomization: Participants in 44 Clinics Not Responding to EIAU and Had LICF Added vs First Randomization: Participants in 12 Clinics Not Responding to EIAU, Continued With EIAU · Wilcoxon (Mann-Whitney) · p = .51 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Median difference (final values): 0.04Difference of distributions of EIAU+LICF versus EIAU. Difference of medians is reported, but the test is non-parametric (comparison of the two distributions and not just medians).
  • Second Randomization: Participants in 15 Clinics Not Responding to LICF+EIAU and Had HICF Added vs Second Randomization: Participants in 14 Clinics Not Responding to LICF+EIAU, Continued With LICF · Wilcoxon (Mann-Whitney) · p = .03 (P-value was not adjusted for multiple comparisons. A priori threshold for statistical significance was .05.) · Median difference (final values): 0.38Difference of distributions of EIAU+LICF+HICF versus EIAU+LICF. Difference of medians is reported, but the test is non-parametric (comparison of the two distributions and not just medians).

Adverse events

Collected over Each clinic was in the study for 30 months, and adverse event data were collected over 30 months for participants in each clinic.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants in 54 Clinics Receiving EIAU Training Only0/90 (0%)0/90 (0%)0/90 (0%)
Participants in 29 Clinics Receiving LICF Training After Non-response to EIAU0/46 (0%)0/46 (0%)0/46 (0%)
Participants in 15 Clinics Receiving HICF Training After Non-response to LICF+EIAU0/24 (0%)0/24 (0%)0/24 (0%)

Baseline characteristics

Clinic personnel from each clinic provided data on their demographic characteristics.

Age, Continuous
Age, Continuous(years)Phase I: Responders to EIAU in 41 ClinicsPhase II: Non-responders to EIAU, Continued EIAU in 12 ClinicsPhase II: Non-responders to EIAU, Responders to Added LICF in 14 ClinicsPhase III: Non-responders to LICF+EIAU, Continued LICFPhase III: Non-responders to LICF+EIAU, HICF AddedPhase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be DeterminedPhase I: EIAU, Dropout Before Response to EIAU Can be DeterminedTotal
Mean41.87 ± 10.6939.47 ± 9.4342.75 ± 10.1944.26 ± 12.1646.86 ± 9.6728.0044.5 ± 6.3642.82 ± 10.65
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Phase I: Responders to EIAU in 41 ClinicsPhase II: Non-responders to EIAU, Continued EIAU in 12 ClinicsPhase II: Non-responders to EIAU, Responders to Added LICF in 14 ClinicsPhase III: Non-responders to LICF+EIAU, Continued LICFPhase III: Non-responders to LICF+EIAU, HICF AddedPhase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be DeterminedPhase I: EIAU, Dropout Before Response to EIAU Can be DeterminedTotal
Sex — Male01000001
Sex — Female681618242411152
Sex — Unknown21300017
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I: Responders to EIAU in 41 ClinicsPhase II: Non-responders to EIAU, Continued EIAU in 12 ClinicsPhase II: Non-responders to EIAU, Responders to Added LICF in 14 ClinicsPhase III: Non-responders to LICF+EIAU, Continued LICFPhase III: Non-responders to LICF+EIAU, HICF AddedPhase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be DeterminedPhase I: EIAU, Dropout Before Response to EIAU Can be DeterminedTotal
Hispanic or Latino1411330123
Not Hispanic or Latino391114181811102
Unknown or Not Reported1766330035
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I: Responders to EIAU in 41 ClinicsPhase II: Non-responders to EIAU, Continued EIAU in 12 ClinicsPhase II: Non-responders to EIAU, Responders to Added LICF in 14 ClinicsPhase III: Non-responders to LICF+EIAU, Continued LICFPhase III: Non-responders to LICF+EIAU, HICF AddedPhase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be DeterminedPhase I: EIAU, Dropout Before Response to EIAU Can be DeterminedTotal
American Indian or Alaska Native00000000
Asian12100004
Native Hawaiian or Other Pacific Islander00000000
Black or African American914480127
White4181114101085
More than one race10013016
Unknown or Not Reported1875530038
Region of Enrollment
Region of Enrollment(participants)Phase I: Responders to EIAU in 41 ClinicsPhase II: Non-responders to EIAU, Continued EIAU in 12 ClinicsPhase II: Non-responders to EIAU, Responders to Added LICF in 14 ClinicsPhase III: Non-responders to LICF+EIAU, Continued LICFPhase III: Non-responders to LICF+EIAU, HICF AddedPhase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be DeterminedPhase I: EIAU, Dropout Before Response to EIAU Can be DeterminedTotal
United States701821242412160
Clinic FQHC status
Clinic FQHC status(Participants)Phase I: Responders to EIAU in 41 ClinicsPhase II: Non-responders to EIAU, Continued EIAU in 12 ClinicsPhase II: Non-responders to EIAU, Responders to Added LICF in 14 ClinicsPhase III: Non-responders to LICF+EIAU, Continued LICFPhase III: Non-responders to LICF+EIAU, HICF AddedPhase II: LICF After Non-response to EIAU, Dropout Before Response to LICF Can be DeterminedPhase I: EIAU, Dropout Before Response to EIAU Can be DeterminedTotal
Yes640340017
No641421212012143
07

Study locations

1 site
  • Michigan State University
    Flint, Michigan 48502, United States
08

References and documents

Publications

  • Johnson JE, Wiltsey-Stirman S, Sikorskii A, Miller T, Poleshuck E, Simas TAM, Carravallah L, Miller R, Zlotnick C. Outcomes of the ROSE Sustainment (ROSES) Study, a sequential multiple assignment randomized implementation trial to determine the minimum necessary intervention to sustain a postpartum depression prevention program in agencies serving low-income pregnant people. Implement Sci. 2025 Feb 10;20(1):9. doi: 10.1186/s13012-025-01420-z. PubMed 39930503 ↗
  • Johnson JE, Wiltsey-Stirman S, Sikorskii A, Miller T, King A, Blume JL, Pham X, Moore Simas TA, Poleshuck E, Weinberg R, Zlotnick C. Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women. Implement Sci. 2018 Aug 22;13(1):115. doi: 10.1186/s13012-018-0807-9. PubMed 30134941 ↗

Study documents

  • Protocol and statistical analysis plan · Jan 30, 2023
  • Informed consent form · Jan 30, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — After data have been collected and study results published, de-identified data will be made available to other qualified researchers upon request, on a CD or other electronic means compatible with our systems. The request will be evaluated by the PIs to ensure that it meets reasonable standards of scientific integrity. We have use standard measures where possible in order to promote data sharing and integration into larger databases and to allow other researchers to analyze the data, including conducting meta-analyses. We will work on the data dictionary throughout the study. Data checking will occur regularly. We will submit primary results for publication by the end of the project period, and will have final de-identified datasets and data dictionaries available by CD within the required time frame.

Supporting information: Study protocol, Sap

09

Registry details

Key details

Study ID
NCT03267563
Lead sponsor
Michigan State University
Collaborators
Butler Hospital, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Palo Alto Veterans Institute for Research, University of Rochester, University of Massachusetts, Worcester, Pacific Institute for Research and Evaluation, National Institute of Mental Health (NIMH)
Responsible party
Jennifer E. Johnson (C. S. Mott Endowed Professor of Public Health, Professor of OBGYN, Professor of Psychiatry and Behavioral Medicine, Michigan State University) — Principal investigator
First posted
Aug 30, 2017
Start date
Jun 12, 2018
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Results posted
Apr 15, 2026
Last update
Apr 15, 2026

Study contacts

Jennifer E Johnson, Ph.D.
principal investigator · Michigan State University
Raven Miller, M.A.
study director · Michigan State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion